RxDoctor Payments Data

Brittany Reynolds, APRN

Family · Cleveland, TXNPI 1548704158

Payments from drug & device makers

$2,296in general payments, 2019–2025

Across 90 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$628
  • Abiomed$276
  • Supernus Pharmaceuticals, Inc.$244
  • Ironshore Pharmaceuticals Inc.$214
  • Lilly USA, LLC$126
  • GSK$113
  • plus $696 from 16 others

What the payments were for

  • Food & beverage$2,296100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,296 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$4,486
Medicare patients
20
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$17,136
OzempicSemaglutide19$16,718
JardianceEmpagliflozin13$10,638
Gabapentin52$872
Nifedipine ErNifedipine26$751
Albuterol Sulfate HfaAlbuterol Sulfate23$600
Atorvastatin Calcium55$530
Levothyroxine Sodium49$459
Losartan Potassium31$424
Metformin Hcl43$420
Fluticasone Propionate31$373
Metoprolol Succinate21$360
Amitriptyline Hcl12$352
Omeprazole21$342
Amlodipine Besylate54$318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$113$17,13613 claims
Novo NordiskOzempic$34$16,71819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Cleveland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →